Adipokines, tumor necrosis factor and its receptors in female patients with systemic lupus erythematosus

Lupus ◽  
2016 ◽  
Vol 26 (1) ◽  
pp. 10-16 ◽  
Author(s):  
F M M Santos ◽  
R W Telles ◽  
C C D Lanna ◽  
A L Teixeira ◽  
A S Miranda ◽  
...  

Objectives To analyze the association of adipokines and tumor necrosis factor α (TNFα) and its receptors with characteristics of systemic lupus erythematosus (SLE) and to investigate the correlation between adipokines and the TNF system. Methods One hundred and thirty-six SLE women, aged ≥18 years old, were assessed. TNFα, soluble TNFα receptors 1 (sTNFR1) and 2 (sTNFR2) and adipokines were analyzed by ELISA kits. Results The median (IQR) of age was 41.5 (33.0–49.7) years old and of disease duration 11.3 (7.8–15.8) years. The median (IQR) of disease activity was 0 (0–4) and of damage index was 2 (1–3). Higher levels of sTNFR1 and sTNFR2 were associated with nephritis ( p < 0.001 for both), and sTNFR1 ( p = 0.025) and TNFα ( p = 0.014) were positively associated with arthritis. Higher sTNFR1 levels were found in participants that were not using antimalarial drugs ( p = 0.04). Independent correlation was found between sTNFR1 (β = 0.253; p = 0.003) and sTNFR2 (β = 0.297; p < 0.001) levels and disease activity and damage index (sTNFR1: β = 0.367; p < 0.001; sTNFR2: β = 0.335; p < 0.001). Higher adiponectin levels were independently associated with nephritis ( p = 0.009) and antimalarial drugs use ( p = 0.015). There was a positive correlation between leptin and sTNFR2 levels ( p = 0.002) and between resistin levels and sTNFR1 ( p < 0.001) and sTNFR2 ( p < 0.001). Conclusion The correlation between adipokines and TNF system allows a better understanding of the role of adipokines in the inflammatory response in SLE patients.

Hypertension ◽  
2010 ◽  
Vol 56 (4) ◽  
pp. 643-649 ◽  
Author(s):  
Marcia Venegas-Pont ◽  
Michaele B. Manigrasso ◽  
Samira C. Grifoni ◽  
Babbette B. LaMarca ◽  
Christine Maric ◽  
...  

2004 ◽  
Vol 33 (6) ◽  
pp. 404-413 ◽  
Author(s):  
Diana Gómez ◽  
Paula A. Correa ◽  
Luis Miguel Gómez ◽  
José Cadena ◽  
José F. Molina ◽  
...  

2021 ◽  
Vol 22 (8) ◽  
pp. 4095
Author(s):  
Neža Brezovec ◽  
Katja Perdan-Pirkmajer ◽  
Saša Čučnik ◽  
Snežna Sodin-Šemrl ◽  
John Varga ◽  
...  

Deregulation of adiponectin is found in systemic autoimmune rheumatic diseases (SARDs). Its expression is downregulated by various inflammatory mediators, but paradoxically, elevated serum levels are present in SARDs with high inflammatory components, such as rheumatoid arthritis and systemic lupus erythematosus. Circulating adiponectin is positively associated with radiographic progression in rheumatoid arthritis as well as with cardiovascular risks and lupus nephritis in systemic lupus erythematosus. However, in SARDs with less prominent inflammation, such as systemic sclerosis, adiponectin levels are low and correlate negatively with disease activity. Regulators of adiponectin gene expression (PPAR-γ, Id3, ATF3, and SIRT1) and inflammatory cytokines (interleukin 6 and tumor necrosis factor α) are differentially expressed in SARDs and could therefore influence total adiponectin levels. In addition, anti-inflammatory therapy could also have an impact, as tocilizumab treatment is associated with increased serum adiponectin. However, anti-tumor necrosis factor α treatment does not seem to affect its levels. Our review provides an overview of studies on adiponectin levels in the bloodstream and other biological samples from SARD patients and presents some possible explanations why adiponectin is deregulated in the context of therapy and gene regulation.


Sign in / Sign up

Export Citation Format

Share Document